ArticleFrontiers in cell and developmental biology2026
FGFR inhibitor resistance in cervical cancer: a role for integrin α2 and mTOR signalling.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the fourth most common cancer among women worldwide and is often diagnosed at advanced stages, highlighting the need for effective systemic therapies, including those targeting key cancer-related pathways. Fibroblast growth factor (FGF) signalling plays a critical role in cell biology, activating FGF receptors (FGFRs) to regulate proliferation, migration and apoptosis. Aberrant activation of the pathway contributes to tumour progression in many cancers, including cervical cancer. FGFR inhibitors (FGFRi) have shown clinical promise but are limited by emergence of therapeutic resistance. Here, we describe mechanisms underpinning FGFRi resistance in three human cervical cancer cell lines (CaSki, HeLa, and SiHa). Transcriptomic analysis identified several genes differentially expressed between parental and resistant lines, including downregulation of Pleckstrin Homology Like Domain Family A Member 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.